{"id":10075,"date":"2026-06-02T14:05:58","date_gmt":"2026-06-02T11:05:58","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=10075"},"modified":"2026-06-02T14:05:58","modified_gmt":"2026-06-02T11:05:58","slug":"ats-2026-american-thoracic-society-international-conference-20-may-2026","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/ats-2026-american-thoracic-society-international-conference-20-may-2026\/","title":{"rendered":"ATS 2026 : (American Thoracic Society International Conference, 20 May 2026)"},"content":{"rendered":"<div class=\"adM\"><br clear=\"all\" \/><br clear=\"all\" \/><\/div>\n<div>\n<div class=\"gmail_signature\" dir=\"ltr\" data-smartmail=\"gmail_signature\">\n<div>ATS 2026 :<br \/>\n(American Thoracic Society International Conference, 20 May 2026)<\/p>\n<p>New Oral Drug Shows Promise for Obstructive Sleep Apnea (OSA)<\/p>\n<p>* AD109, a once-daily oral medication, significantly improved OSA in patients unable or unwilling to use CPAP.<br \/>\n* Combines:<br \/>\n* Atomoxetine<br \/>\n* Aroxybutynin<br \/>\n* Reduced loud snoring by 70% (vs 26% with placebo).<br \/>\n* No serious treatment-related adverse events were reported.<br \/>\n* May become the first effective oral therapy for OSA, either alone or combined with GLP-1\u2013based weight-loss therapies such as tirzepatide.<\/p>\n<p>Take-Home Message<\/p>\n<p>AD109 significantly reduced sleep apnea severity, and snoring for patients who cannot tolerate CPAP.<\/p>\n<p><a href=\"https:\/\/www.medscape.com\/viewarticle\/pill-development-could-improve-obstructive-sleep-apnea-2026a1000h41\" target=\"_blank\" data-saferedirecturl=\"https:\/\/www.google.com\/url?q=https:\/\/www.medscape.com\/viewarticle\/pill-development-could-improve-obstructive-sleep-apnea-2026a1000h41&amp;source=gmail&amp;ust=1780484716752000&amp;usg=AOvVaw0jwz4kAZw35fQo-9oUySiX\" rel=\"noopener\">https:\/\/www.medscape.com\/<wbr \/>viewarticle\/pill-development-<wbr \/>could-improve-obstructive-<wbr \/>sleep-apnea-2026a1000h41<\/a><\/div>\n<div><\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>ATS 2026 : (American Thoracic Society International Conference, 20 May 2026) New Oral Drug Shows Promise for Obstructive Sleep Apnea (OSA) * AD109, a once-daily oral medication, significantly improved OSA in patients unable or unwilling to use CPAP. * Combines: * Atomoxetine * Aroxybutynin * Reduced loud snoring by 70% (vs 26% with placebo). * [&hellip;]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-10075","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/10075","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=10075"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/10075\/revisions"}],"predecessor-version":[{"id":10076,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/10075\/revisions\/10076"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=10075"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=10075"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=10075"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}